Safety, efficacy and pharmacokinetics of BPI-9016M in c-MET overexpression or MET exon 14 skipping mutation patients with locally advanced or metastatic non-small-cell lung cancer: a phase Ib study.
Hu X, Cui X, Wang Z, Liu Y, Luo Y, Zhong W, Zhao H, Yao M, Jiang D, Wang M, Chen M, Zheng X, Ding L, Wang Y, Yuan X, Wu P, Hu B, Han X, Shi Y.
Hu X, et al. Among authors: wang z, wang y, wang m.
BMC Cancer. 2023 Apr 11;23(1):331. doi: 10.1186/s12885-022-10500-y.
BMC Cancer. 2023.
PMID: 37041472
Free PMC article.
Clinical Trial.